The latest announcement is out from Intellia Therapeutics (NTLA).
Intellia Therapeutics, Inc. has appointed Brian Goff as a Class I director, whose term will end at the 2026 annual meeting of stockholders. Goff, deemed independent by Nasdaq’s listing rules, brings over thirty years of experience in the biopharmaceutical industry, including executive roles at Agios Pharmaceuticals, Alexion Pharmaceuticals, and Baxalta. Alongside his directorship, he will serve on the Compensation and Talent Development Committee and has been granted stock options and restricted stock units as part of his compensation.
See more insights into NTLA stock on TipRanks’ Stock Analysis page.
